\-\ Texto\\:\\ \ \(0\)\
\-\ the\\ patient\\ presented\\ with\\ drowsiness\\,\\ weariness\\ in\\ upper\\ and\\ lower\\ limbs\\ and\\ gait\\ difficulties\\.\ \(0\)\
\-\ bp\\ 180\\/110\\ mmhg\ \(0\)\
\-\ mri\\ findings\\ of\\ bilateral\\ and\\ symmetric\\ basal\\ ganglia\\ involvement\\,\\ but\\ diagnosis\\ of\\ exclusion\\ after\\ ruling\\ out\\ \\(by\\ laboratory\\ and\\ clinical\\ and\\ mri\\ evolution\\)\\ of\\ other\\ possible\\ causes\\.\\ after\\ recovering\\ from\\ the\\ hellp\\ syndrome\\,\\ pre\\-eclampsia\\ and\\ normalization\\ of\\ the\\ high\\-blood\\ pressure\\,\\ the\\ patient\\ experienced\\ a\\ quick\\ and\\ complete\\ recovery\\.\\ subsequent\\ mri\\ 2\\ weeks\\ later\\ was\\ completely\\ normal\\.\ \(0\)\
\-\ anti\\-hypertensive\\ and\\ supportive\\ treatment\\ with\\ favorable\\ evolution\\.\ \(0\)\
\-\ lentiform\\ fork\\ sign\\ in\\ hellp\\ syndrome\\.\\ bilateral\\ symmetric\\ hypodensity\\ of\\ the\\ basal\\ ganglia\\ on\\ non\\-enhanced\\ ct\\,\\ without\\ enhancement\\ after\\ contrast\\ administration\\.\\ subsequent\\ mri\\ showed\\ hypointense\\ areas\\ on\\ t1wi\\ and\\ high\\ intensity\\ on\\ t2wi\\ and\\ flair\\,\\ consistent\\ with\\ vasogenic\\ edema\\ involving\\ symmetrically\\ globus\\ pallidus\\,\\ putamen\\,\\ internal\\ and\\ external\\ capsules\\,\\ but\\ tiny\\ areas\\ of\\ diffusion\\ restriction\\ were\\ present\\.\ \(0\)\
\-\ follow\\-up\\ mri\\ 2\\ weeks\\ later\\ showed\\ complete\\ resolution\\ of\\ the\\ imaging\\ findings\\.\ \(0\)\
\-\ lentiform\\ fork\\ sign\\ of\\ basal\\ ganglia\\ in\\ hellp\\ syndrome\\.\ \(0\)\
\-\ acute\\ uremic\\ encephalopathies\\,\\ typically\\ acute\\ glomerulonephritis\\,\\ hemolytic\\-uremic\\ syndrome\\ and\\ thrombotic\\ thrombocytopenic\\ purpura\\.\ \(0\)\
\-\ systemic\\ metabolic\\ acidosis\\.\ \(0\)\
\-\ toxins\\ such\\ as\\ methanol\\ and\\ carbon\\ monoxide\\.\ \(0\)\
\-\ etiologies\\ of\\ acute\\ hypoxia\\.\ \(0\)\
\-\ metabolic\\ conditions\\ as\\ mitochondrial\\ disorders\\ could\\ also\\ be\\ included\\ in\\ the\\ differential\\.\ \(0\)\
\-\ symmetric\\ vasculitis\\-like\\ processes\\ related\\ to\\ tuberculosis\\ and\\ fungal\\ basal\\ meningitis\\ could\\ also\\ involve\\ bilaterally\\ the\\ basal\\ ganglia\\.\ \(0\)\
\-\ deep\\ veins\\ thrombosis\\.\ \(0\)\
\-\ 24\\ y\\.o\\.\\ woman\\ with\\ hellp\\ syndrome\\ \\(hemolysis\\,\\ elevated\\ liver\\,\\ low\\ platelets\\)\\ and\\ severe\\ pre\\-eclampsia\\ with\\ high\\ blood\\ pressure\\ \\(180\\/110\\ mmhg\\)\\.\ \(0\)\
\-\ lentiform\\ fork\\ sign\\ was\\ classically\\ described\\ in\\ acute\\ uremic\\ encephalopathies\\ and\\ it\\ was\\ explained\\ by\\ both\\ acute\\ uremia\\ and\\ associated\\ metabolic\\ acidosis\\.\\ acute\\ uremic\\ encephalopathies\\ in\\ which\\ this\\ sign\\ was\\ typically\\ described\\ included\\ acute\\ glomerulonephritis\\,\\ hemolytic\\-uremic\\ syndrome\\ and\\ thrombotic\\ thrombocytopenic\\ purpura\\.\\ \ \(0\)\
\-\ classical\\ described\\ mri\\ findings\\ were\\ relatively\\ symmetric\\ edema\\ in\\ the\\ globus\\ pallidus\\ and\\ putamen\\,\\ with\\ extension\\ to\\ the\\ internal\\ and\\ external\\ capsules\\,\\ associated\\ with\\ some\\ mass\\ effect\\.\ \(0\)\
\-\ the\\ differential\\ diagnosis\\ includes\\ hypoxia\\ and\\ toxins\\ as\\ methanol\\ and\\ carbon\\ monoxide\\.\\ metabolic\\ conditions\\ as\\ mitochondrial\\ disorders\\ could\\ also\\ be\\ included\\ in\\ the\\ differential\\.\\ symmetric\\ vasculitis\\-like\\ processes\\ related\\ to\\ tuberculosis\\ and\\ fungal\\ basal\\ meningitis\\ could\\ also\\ involve\\ bilateraly\\ the\\ basal\\ ganglia\\.\ \(0\)\
\-\ http\\:\\/\\/www\\.aafp\\.org\\/afp\\/1999\\/0901\\/p829\\.html\ \(1\)\
\-\ references\\:\ \(0\)\
\-\ rathi\\ m\\,\\ mudrabettu\\ c\\.\\ lentiform\\ fork\\ sign\\ in\\ a\\ case\\ of\\ end\\-stage\\ renal\\ disease\\.\\ kidney\\ international\\ 2012\\;\\ 82\\,\\ 365\\.\ \(0\)\
\-\ jeong\\ yk\\,\\ kim\\ lo\\,\\ kim\\ ws\\,\\ et\\ al\\.\\ hemolytic\\ uremic\\ syndrome\\:\\ mr\\ findings\\ of\\ cns\\ complications\\.\\ pediatr\\ radiol\\ 1994\\;\\ 24\\:585\\-586\\.\ \(0\)\
\-\ moore\\ kr\\,\\ osborn\\ ag\\,\\ townsend\\ jj\\,\\ et\\ al\\.\\ the\\ imaging\\ and\\ pathologic\\ spectrum\\ of\\ hus\\-tfp\\.\\ j\\ neuroradiol\\ 1997\\;\\ 3\\:147\\-159\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hellp\\:\\ 0\\.07439256053980167\ \(0\)\
\-\ fork\\:\\ 0\\.07439256053980167\ \(0\)\
\-\ uremic\\:\\ 0\\.06854321724393715\ \(0\)\
\-\ lentiform\\:\\ 0\\.060810806004492804\ \(0\)\
\-\ basal\\:\\ 0\\.05752903478263421\ \(0\)\
\-\ encephalopathies\\:\\ 0\\.048841178071508784\ \(0\)\
\-\ ganglia\\:\\ 0\\.04612729079616225\ \(0\)\
\-\ symmetric\\:\\ 0\\.0411694466058064\ \(0\)\
\-\ 180\\/110\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ hemolytic\\-uremic\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ vasculitis\\-like\\:\\ 0\\.037196280269900836\ \(0\)\
\-\ syndrome\\:\\ 0\\.036091447335743654\ \(0\)\
\-\ metabolic\\:\\ 0\\.03561517783824395\ \(0\)\
\-\ sign\\:\\ 0\\.031228338626203278\ \(0\)\
\-\ acute\\:\\ 0\\.031158555493133896\ \(0\)\
\-\ pre\\-eclampsia\\:\\ 0\\.030405403002246402\ \(0\)\
\-\ capsules\\:\\ 0\\.029636113733073597\ \(0\)\
\-\ thrombocytopenic\\:\\ 0\\.029636113733073597\ \(0\)\
\-\ toxins\\:\\ 0\\.02898568892367588\ \(0\)\
\-\ methanol\\:\\ 0\\.02898568892367588\ \(0\)\
\-\ mitochondrial\\:\\ 0\\.02898568892367588\ \(0\)\
\-\ pallidus\\:\\ 0\\.027480731354314142\ \(0\)\
\-\ purpura\\:\\ 0\\.027480731354314142\ \(0\)\
\-\ kim\\:\\ 0\\.027480731354314142\ \(0\)\
\-\ glomerulonephritis\\:\\ 0\\.026711442085141337\ \(0\)\
\-\ could\\:\\ 0\\.026603864504899172\ \(0\)\
\-\ putamen\\:\\ 0\\.026061017275743625\ \(0\)\
\-\ monoxide\\:\\ 0\\.026061017275743625\ \(0\)\
\-\ globus\\:\\ 0\\.0254975936781718\ \(0\)\
\-\ thrombotic\\:\\ 0\\.0254975936781718\ \(0\)\
\-\ carbon\\:\\ 0\\.02500061884417862\ \(0\)\
\-\ included\\:\\ 0\\.024938741144084474\ \(0\)\
\-\ mri\\:\\ 0\\.02485159310018506\ \(0\)\
\-\ evolution\\:\\ 0\\.024350194034780906\ \(0\)\
\-\ acidosis\\:\\ 0\\.023289795603215903\ \(0\)\
\-\ described\\:\\ 0\\.023033979059447273\ \(0\)\
\-\ hypoxia\\:\\ 0\\.022845236465419163\ \(0\)\
\-\ mmhg\\:\\ 0\\.021960339710220562\ \(0\)\
\-\ processes\\:\\ 0\\.01951841216008469\ \(0\)\
\-\ meningitis\\:\\ 0\\.018706716410517365\ \(0\)\
\-\ weariness\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ high\\-blood\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ hemolysis\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ \\/\\/www\\.aafp\\.org\\/afp\\/1999\\/0901\\/p829\\.html\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ \\-rathi\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ mudrabettu\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 365\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ \\-jeong\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ yk\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 24\\:585\\-586\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ \\-moore\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ hus\\-tfp\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ 3\\:147\\-159\\:\\ 0\\.018598140134950418\ \(0\)\
\-\ conditions\\:\\ 0\\.017937427141344563\ \(0\)\
\-\ fungal\\:\\ 0\\.017479702909302074\ \(0\)\
\-\ disorders\\:\\ 0\\.017249496224701084\ \(0\)\
\-\ tuberculosis\\:\\ 0\\.01717546960170147\ \(0\)\
\-\ differential\\:\\ 0\\.017170631831347656\ \(0\)\
\-\ kr\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ townsend\\:\\ 0\\.017135804310984288\ \(0\)\
\-\ involve\\:\\ 0\\.01699589316955465\ \(0\)\
\-\ drowsiness\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ anti\\-hypertensive\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ bilateraly\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ lo\\:\\ 0\\.016280392690502927\ \(0\)\
\-\ findings\\:\\ 0\\.015348834901181092\ \(0\)\
\-\ external\\:\\ 0\\.015332214656854063\ \(0\)\
\-\ al\\:\\ 0\\.01528506992859193\ \(0\)\
\-\ uremia\\:\\ 0\\.015202701501123201\ \(0\)\
\-\ ws\\:\\ 0\\.015202701501123201\ \(0\)\
\-\ related\\:\\ 0\\.014882917271189717\ \(0\)\
\-\ quick\\:\\ 0\\.014818056866536799\ \(0\)\
\-\ et\\:\\ 0\\.014756955401359838\ \(0\)\
\-\ normalization\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ non\\-enhanced\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ jj\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ neuroradiol\\:\\ 0\\.01449284446183794\ \(0\)\
\-\ also\\:\\ 0\\.014216199102701698\ \(0\)\
\-\ ruling\\:\\ 0\\.014211132663052028\ \(0\)\
\-\ pressure\\:\\ 0\\.014160054471824215\ \(0\)\
\-\ subsequent\\:\\ 0\\.014036205475990765\ \(0\)\
\-\ osborn\\:\\ 0\\.01396264524605544\ \(0\)\
\-\ \\,\\:\\ 0\\.01370683876036898\ \(0\)\
\-\ hemolytic\\:\\ 0\\.013355721042570668\ \(0\)\
\-\ pediatr\\:\\ 0\\.013030508637871812\ \(0\)\
\-\ ag\\:\\ 0\\.013030508637871812\ \(0\)\
\-\ later\\:\\ 0\\.013018644054822462\ \(0\)\
\-\ recovering\\:\\ 0\\.012884954056675712\ \(0\)\
\-\ end\\-stage\\:\\ 0\\.012884954056675712\ \(0\)\
\-\ \\;\\:\\ 0\\.012819121445902491\ \(0\)\
\-\ symmetrically\\:\\ 0\\.0127487968390859\ \(0\)\
\-\ classical\\:\\ 0\\.0127487968390859\ \(0\)\
\-\ radiol\\:\\ 0\\.0127487968390859\ \(0\)\
\-\ typically\\:\\ 0\\.012727534892430262\ \(0\)\
\-\ complete\\:\\ 0\\.012689349932430607\ \(0\)\
\-\ international\\:\\ 0\\.012620896793059666\ \(0\)\
\-\ limbs\\:\\ 0\\.012175097017390453\ \(0\)\
\-\ restriction\\:\\ 0\\.012175097017390453\ \(0\)\
\-\ explained\\:\\ 0\\.012175097017390453\ \(0\)\
\-\ 1994\\:\\ 0\\.012175097017390453\ \(0\)\
\-\ areas\\:\\ 0\\.012132266545342052\ \(0\)\
\-\ internal\\:\\ 0\\.012088083845480047\ \(0\)\
\-\ exclusion\\:\\ 0\\.012076953524489835\ \(0\)\
\-\ showed\\:\\ 0\\.011821954716977622\ \(0\)\
\-\ favorable\\:\\ 0\\.011724518746719441\ \(0\)\
\-\ platelets\\:\\ 0\\.011724518746719441\ \(0\)\
\-\ difficulties\\:\\ 0\\.011644897801607951\ \(0\)\
\-\ 2012\\:\\ 0\\.01149414049362874\ \(0\)\
\-\ tiny\\:\\ 0\\.01128646101511977\ \(0\)\
\-\ after\\:\\ 0\\.011189881029172167\ \(0\)\
\-\ 82\\:\\ 0\\.011158560969093536\ \(0\)\
\-\ hypodensity\\:\\ 0\\.011097405828010725\ \(0\)\
\-\ t1wi\\:\\ 0\\.011097405828010725\ \(0\)\
\-\ as\\:\\ 0\\.010907827053958883\ \(0\)\
\-\ t2wi\\:\\ 0\\.010815694029224813\ \(0\)\
\-\ classically\\:\\ 0\\.01052083761071182\ \(0\)\
\-\ c\\.\\:\\ 0\\.010431049394638412\ \(0\)\
\-\ spectrum\\:\\ 0\\.010431049394638412\ \(0\)\
\-\ weeks\\:\\ 0\\.010233239480595561\ \(0\)\
\-\ edema\\:\\ 0\\.010197989406883082\ \(0\)\
\-\ 1997\\:\\ 0\\.010105836989939554\ \(0\)\
\-\ etiologies\\:\\ 0\\.009995740464263245\ \(0\)\
\-\ high\\:\\ 0\\.009867282958130023\ \(0\)\
\-\ recovery\\:\\ 0\\.009824125191153641\ \(0\)\
\-\ vasogenic\\:\\ 0\\.009759206080042345\ \(0\)\
\-\ experienced\\:\\ 0\\.009353358205258682\ \(0\)\
\-\ m\\:\\ 0\\.009301264085869714\ \(0\)\
\-\ cns\\:\\ 0\\.00922545815923245\ \(0\)\
\-\ and\\:\\ 0\\.009114380037074352\ \(0\)\
\-\ bilateral\\:\\ 0\\.008750285777698074\ \(0\)\
\-\ completely\\:\\ 0\\.008662422410662793\ \(0\)\
\-\ systemic\\:\\ 0\\.008624748112350542\ \(0\)\
\-\ veins\\:\\ 0\\.008624748112350542\ \(0\)\
\-\ hypointense\\:\\ 0\\.008551359681790594\ \(0\)\
\-\ associated\\:\\ 0\\.00850828085193123\ \(0\)\
\-\ imaging\\:\\ 0\\.008447568879559504\ \(0\)\
\-\ gait\\:\\ 0\\.008395013748976835\ \(0\)\
\-\ was\\:\\ 0\\.008339894702225204\ \(0\)\
\-\ diagnosis\\:\\ 0\\.008279406458989112\ \(0\)\
\-\ flair\\:\\ 0\\.008265144776404191\ \(0\)\
\-\ were\\:\\ 0\\.008186862180126249\ \(0\)\
\-\ j\\:\\ 0\\.00814280878980008\ \(0\)\
\-\ diffusion\\:\\ 0\\.008069801344277977\ \(0\)\
\-\ in\\:\\ 0\\.00800121323051117\ \(0\)\
\-\ supportive\\:\\ 0\\.007971657851377361\ \(0\)\
\-\ pathologic\\:\\ 0\\.007891022381292554\ \(0\)\
\-\ bp\\:\\ 0\\.00782610327018126\ \(0\)\
\-\ resolution\\:\\ 0\\.007775569006420727\ \(0\)\
\-\ 2\\:\\ 0\\.0077641539937153845\ \(0\)\
\-\ thrombosis\\:\\ 0\\.007738447145892499\ \(0\)\
\-\ relatively\\:\\ 0\\.007714057225215124\ \(0\)\
\-\ but\\:\\ 0\\.0076898873461330695\ \(0\)\
\-\ references\\:\\ 0\\.007495418217429562\ \(0\)\
\-\ administration\\:\\ 0\\.007484515326799937\ \(0\)\
\-\ deep\\:\\ 0\\.007297325209482036\ \(0\)\
\-\ includes\\:\\ 0\\.0072676801599975424\ \(0\)\
\-\ \\:\\:\\ 0\\.007153638075890285\ \(0\)\
\-\ complications\\:\\ 0\\.007143824462050753\ \(0\)\
\-\ causes\\:\\ 0\\.007018102737995383\ \(0\)\
\-\ 24\\:\\ 0\\.007009402912712973\ \(0\)\
\-\ http\\:\\ 0\\.006826558223587079\ \(0\)\
\-\ laboratory\\:\\ 0\\.006643653451168915\ \(0\)\
\-\ involvement\\:\\ 0\\.006607465520311848\ \(0\)\
\-\ intensity\\:\\ 0\\.006516182861559706\ \(0\)\
\-\ extension\\:\\ 0\\.00643528970713429\ \(0\)\
\-\ effect\\:\\ 0\\.006383034289175622\ \(0\)\
\-\ kidney\\:\\ 0\\.006351019947362889\ \(0\)\
\-\ involving\\:\\ 0\\.006325753721525935\ \(0\)\
\-\ liver\\:\\ 0\\.006215657195849628\ \(0\)\
\-\ elevated\\:\\ 0\\.00611670118430182\ \(0\)\
\-\ possible\\:\\ 0\\.006071692444903105\ \(0\)\
\-\ by\\:\\ 0\\.006003674697235758\ \(0\)\
\-\ out\\:\\ 0\\.005957919571431468\ \(0\)\
\-\ bilaterally\\:\\ 0\\.00592131906861583\ \(0\)\
\-\ follow\\-up\\:\\ 0\\.005865056943969919\ \(0\)\
\-\ mr\\:\\ 0\\.005728268928157034\ \(0\)\
\-\ such\\:\\ 0\\.005635723185318253\ \(0\)\
\-\ be\\:\\ 0\\.005560154950818266\ \(0\)\
\-\ clinical\\:\\ 0\\.005547067088746844\ \(0\)\
\-\ severe\\:\\ 0\\.005547067088746844\ \(0\)\
\-\ some\\:\\ 0\\.0054745321811535\ \(0\)\
\-\ renal\\:\\ 0\\.0054166150832448716\ \(0\)\
\-\ y\\.o\\:\\ 0\\.005203332136258861\ \(0\)\
\-\ low\\:\\ 0\\.005013012769760336\ \(0\)\
\-\ blood\\:\\ 0\\.004920698465209492\ \(0\)\
\-\ presented\\:\\ 0\\.004914256613971327\ \(0\)\
\-\ enhancement\\:\\ 0\\.004832254780850287\ \(0\)\
\-\ both\\:\\ 0\\.004603797448704897\ \(0\)\
\-\ on\\:\\ 0\\.0045815886858571395\ \(0\)\
\-\ \\(\\:\\ 0\\.004571909659771269\ \(0\)\
\-\ \\)\\:\\ 0\\.004516061342489272\ \(0\)\
\-\ consistent\\:\\ 0\\.004420460482766251\ \(0\)\
\-\ upper\\:\\ 0\\.004350380813014173\ \(0\)\
\-\ without\\:\\ 0\\.004244753515523544\ \(0\)\
\-\ woman\\:\\ 0\\.0041643522098922066\ \(0\)\
\-\ other\\:\\ 0\\.004155355587979849\ \(0\)\
\-\ the\\:\\ 0\\.004083312206436205\ \(0\)\
\-\ present\\:\\ 0\\.004071748426016204\ \(0\)\
\-\ lower\\:\\ 0\\.004054561327771862\ \(0\)\
\-\ it\\:\\ 0\\.0040524227521793596\ \(0\)\
\-\ contrast\\:\\ 0\\.004035391744320475\ \(0\)\
\-\ case\\:\\ 0\\.003944102179044875\ \(0\)\
\-\ treatment\\:\\ 0\\.0036489809274280315\ \(0\)\
\-\ patient\\:\\ 0\\.003614311944794886\ \(0\)\
\-\ which\\:\\ 0\\.0033652839393302713\ \(0\)\
\-\ of\\:\\ 0\\.0029494633113414793\ \(0\)\
\-\ disease\\:\\ 0\\.0029467036734508525\ \(0\)\
\-\ normal\\:\\ 0\\.0028261866130782722\ \(0\)\
\-\ to\\:\\ 0\\.00270296271166447\ \(0\)\
\-\ from\\:\\ 0\\.002671805302013106\ \(0\)\
\-\ ct\\:\\ 0\\.0025217376653840565\ \(0\)\
\-\ mass\\:\\ 0\\.002507301702421022\ \(0\)\
\-\ \\.\\:\\ 0\\.002471486690321576\ \(0\)\
\-\ this\\:\\ 0\\.002027715639903234\ \(0\)\
\-\ with\\:\\ 0\\.0017279097734793842\ \(0\)\
\-\ a\\:\\ 0\\.0016734168853105537\ \(0\)\
